ArticleACS medicinal chemistry letters2024

Targeted Combination Therapies: A New Frontier in the Treatment of TP53 and KRAS Mutation-Associated Cancers.

Robert B KargboPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.